Validation of GPR65 as a Novel Immuno-oncology Target using Advanced In Vitro & In Vivo Models

Time: 4:30 pm
day: Day One PM


  • Identification of GPR65 as a novel immuno-oncology target as well as potent GPR65 inhibitors
  • Provide additional validation using primary tumorhistocultures and genetically engineered mice
  • Advancing biomarker development to accelerate clinical development